Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1897 1
1912 1
1920 2
1924 1
1925 1
1927 1
1928 1
1929 2
1934 1
1936 1
1937 4
1939 2
1942 2
1943 3
1944 2
1945 6
1946 1
1947 2
1948 2
1950 2
1951 2
1952 1
1953 6
1954 1
1955 2
1956 5
1957 2
1958 2
1959 4
1960 2
1961 5
1962 3
1964 8
1965 6
1966 4
1967 7
1968 5
1969 3
1970 2
1971 4
1972 2
1973 4
1974 1
1975 4
1976 1
1977 3
1978 6
1979 7
1980 10
1981 4
1982 7
1983 6
1984 6
1985 7
1986 6
1987 7
1988 13
1989 11
1990 8
1991 10
1992 5
1993 7
1994 8
1995 7
1996 4
1997 9
1998 6
1999 6
2000 10
2001 15
2002 19
2003 11
2004 7
2005 18
2006 24
2007 24
2008 17
2009 30
2010 23
2011 41
2012 40
2013 45
2014 42
2015 39
2016 37
2017 51
2018 43
2019 48
2020 57
2021 55
2022 49
2023 43
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

992 results

Results by year

Filters applied: . Clear all
Page 1
Phase 2 trial of regorafenib in recurrent or metastatic adenoid cystic carcinoma.
Desilets A, Vos JL, Katabi N, Kuo F, Nadeem Z, Linxweiler M, Ostrovnaya I, Baxi S, Dunn LA, Sherman EJ, Pfister DG, Morris LGT, Ho AL. Desilets A, et al. Among authors: dunn la. Clin Cancer Res. 2024 Oct 1. doi: 10.1158/1078-0432.CCR-24-1064. Online ahead of print. Clin Cancer Res. 2024. PMID: 39352719
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6.
Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D. Hughes BGM, et al. Among authors: dunn la. J Am Acad Dermatol. 2024 Sep 6:S0190-9622(24)02770-1. doi: 10.1016/j.jaad.2024.06.108. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39245360
The impact of hindsight bias on the diagnosis of perioperative events by anesthesia providers: A multicenter randomized crossover study.
Millan PD, Kleiman AM, Friedman JF, Dunn LK, Gui JL, Bechtel AJ, Collins SR, Huffmyer JL, Dwivedi P, Wolpaw JT, Nemergut EC, Tsang S, Forkin KT. Millan PD, et al. Among authors: dunn lk. J Clin Anesth. 2024 Oct;97:111549. doi: 10.1016/j.jclinane.2024.111549. Epub 2024 Jul 13. J Clin Anesth. 2024. PMID: 39002404 Clinical Trial.
992 results